GR
GRFS.US Grifols SA ADR
- Market cap
- USD 5.91B
- P/E
- 10.5x
- P/B
- 0.93x
- ROE
- 9.6%
- Dividend yield
- 1.22%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GRFS.US undervalued?
Graham numberGRFS.US trades 34.4% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Grifols SA ADR fundamental analysis
No fundamental analysis for Grifols SA ADR yet.
Grifols SA ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Grifols SA ADR
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and mark…
Full company profileGrifols SA ADR financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Grifols SA ADR annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.05B | 4.32B | 4.49B | 5.10B | 5.34B | 4.93B | 6.06B | 6.59B | 7.21B | 7.23B | 7.52B |
| Gross Profit | 1.91B | 2.15B | 2.05B | 2.34B | 2.26B | 1.96B | 2.21B | 2.48B | 2.79B | 2.58B | 2.87B |
| Operating Income | 939M | 1.00B | 994M | 1.13B | 996M | 595M | 782M | 782M | 1.19B | 1.19B | 1.35B |
| EBITDA | 1.15B | 1.19B | 1.26B | 1.44B | 1.42B | 944M | 1.19B | 1.17B | 1.48B | 1.62B | 1.92B |
| Net Income | 545M | 663M | 597M | 625M | 619M | 189M | 185M | 42.3M | 157M | 386M | 556M |
| EPS | 0.80 | 0.97 | 0.87 | 0.94 | 0.90 | 0.28 | 0.27 | 0.06 | 0.23 | 0.57 | 0.82 |
| Balance Sheet | |||||||||||
| Total Assets | 10.1B | 10.9B | 12.5B | 17.4B | 15.3B | 19.2B | 21.2B | 21.0B | 21.4B | 19.7B | 20.3B |
| Total Liabilities | 6.40B | 7.29B | 7.78B | 9.75B | 8.55B | 11.9B | 13.3B | 13.5B | 12.8B | 12.1B | 12.0B |
| Shareholders' Equity | 3.72B | 3.63B | 4.23B | 5.41B | 5.11B | 5.52B | 5.65B | 5.37B | 5.88B | 5.27B | 5.79B |
| Cash & Short-term Investments | 895M | 887M | 1.03B | 2.76B | 591M | 2.69B | 580M | 646M | 1.00B | 825M | 486M |
| Total Debt | 4.89B | 6.01B | 6.03B | 7.98B | 6.91B | 10.2B | 9.75B | 11.0B | 10.1B | 8.74B | 9.24B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 553M | 842M | 737M | 569M | 1.11B | 597M | -10.9M | 219M | 902M | 1.01B | 917M |
| Capital Expenditure | 293M | 323M | 308M | 412M | 363M | 315M | 376M | 310M | 371M | 255M | 317M |
| Free Cash Flow | 261M | 519M | 430M | 157M | 748M | 282M | -386M | -91.6M | 531M | 751M | 600M |
| Ratios | |||||||||||
| ROE | 14.7% | 18.3% | 14.1% | 11.5% | 12.1% | 3.4% | 3.3% | 0.8% | 2.7% | 7.3% | 9.6% |
| ROA | 5.4% | 6.1% | 4.8% | 3.6% | 4.0% | 1.0% | 0.9% | 0.2% | 0.7% | 2.0% | 2.7% |
| Net Profit Margin | 13.5% | 15.3% | 13.3% | 12.3% | 11.6% | 3.8% | 3.1% | 0.6% | 2.2% | 5.3% | 7.4% |
| Debt to Equity | 1.31x | 1.66x | 1.43x | 1.47x | 1.35x | 1.84x | 1.73x | 2.05x | 1.71x | 1.66x | 1.60x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Grifols SA ADR dividends
- Dividend yield
- 1.22%
- Forward dividend
- 0.11 USD
- Payout ratio
- 31.8%
- Ex-dividend date
- Jul 2, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 123M | 0.18 | 31.8% |
| 2024 | EUR 962K | 0.00 | 0.6% |
| 2023 | - | - | - |
| 2022 | EUR 592K | 0.00 | 0.3% |
| 2021 | EUR 259M | 0.38 | 137.2% |
| 2020 | EUR 113M | 0.17 | 18.3% |
| 2019 | EUR 239M | 0.36 | 38.2% |
| 2018 | EUR 279M | 0.41 | 46.7% |
| 2017 | EUR 218M | 0.32 | 32.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jan 4, 2016.
Who owns Grifols SA ADR
- Insiders 0.92%
- Institutions 56.94%
- Public & others 42.14%
- Shares outstanding 258M
- Free float 836M
Top funds holding GRFS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| American Funds New Perspective A | 14.0M | 2.06% | 0.00% | Sep 2026 |
| American Funds Intl Gr and Inc F-2 | 5.18M | 0.76% | 0.00% | Sep 2026 |
| Brandes International Small Cap Equity A | 4.73M | 0.69% | 0.00% | Sep 2026 |
| Brandes Global Small Cap Equity Cl F | 3.47M | 0.51% | 0.00% | Oct 2026 |
| United International Eq Alpha Corp Cl A | 2.25M | 0.33% | +11.83% | Mar 2026 |
| Brandes Small Cap Value R6 | 2.15M | 0.32% | +2.28% | Sep 2026 |
| iShares Biotechnology ETF | 1.81M | 0.27% | -0.19% | Oct 2026 |
| CI International Equity Fund F | 1.67M | 0.25% | 0.00% | Jun 2026 |
| Capital Group NewPers LUX Z | 1.56M | 0.23% | 0.00% | Jul 2026 |
| Capital Group GNewPers LUX P | 1.09M | 0.16% | 0.00% | Jul 2026 |
| MGI Global Equity M-7 € Acc | 1.03M | 0.15% | +5.39% | Sep 2026 |
| Brandes International ETF | 923K | 0.14% | 0.00% | Oct 2026 |
| Brandes Global Equity F | 815K | 0.12% | 0.00% | Oct 2026 |
| CI Global Balanced Fund F | 601K | 0.09% | -12.92% | Jun 2026 |
| Mercer Global Small Cap Equity M-5£ | 541K | 0.08% | 0.00% | Sep 2026 |
| AXA Capital Global Equity Inst I JPY Acc | 520K | 0.08% | 0.00% | Oct 2026 |
| CI Global Equity Alpha Private Pool A | 367K | 0.05% | 0.00% | Jun 2026 |
| Stt Strt®SPDR®S&PKenshoNwEcosComposETF | 348K | 0.05% | +0.08% | Oct 2026 |
| Brandes U.S. Small-Mid Cap Value ETF | 344K | 0.05% | 0.00% | Oct 2026 |
| CI Global Balanced Corporate F | 336K | 0.05% | -22.44% | Jun 2026 |
Top institutions holding GRFS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Brandes Investment Partners & Co | 37.8M | 5.56% | +4.08% | Jun 2026 |
| Capital World Investors | 22.9M | 3.37% | -0.06% | Jun 2026 |
| Permian Investment Partners | 19.7M | 2.90% | +1.99% | Jun 2026 |
| Bank of America Corp | 6.55M | 0.96% | +51.37% | Jun 2026 |
| Millennium Management LLC | 4.37M | 0.64% | -12.70% | Jun 2026 |
| Flat Footed LLC | 4.35M | 0.64% | +216.94% | Jun 2026 |
| Jupiter Topco LLC | 2.96M | 0.43% | 0.00% | Jun 2026 |
| Armistice Capital, LLC | 2.94M | 0.43% | -1.74% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.66M | 0.39% | -6.89% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 2.65M | 0.39% | -2.82% | Jun 2026 |
| New York State Common Retirement Fund | 2.45M | 0.36% | 0.00% | Jun 2026 |
| BlackRock Inc | 2.03M | 0.30% | +34.27% | Jun 2026 |
| JPMorgan Chase & Co | 1.93M | 0.28% | -28.64% | Jun 2026 |
| NORGES BANK | 1.84M | 0.27% | -5.15% | Jun 2026 |
| UBS Group AG | 1.83M | 0.27% | -42.07% | Jun 2026 |
| Whitebox Advisors, LLC | 1.60M | 0.24% | -22.45% | Jun 2026 |
| Tidal Investments LLC. | 1.23M | 0.18% | +9.76% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.18M | 0.17% | -11.10% | Jun 2026 |
| SEI Investments Co | 1.11M | 0.16% | -11.24% | Jun 2026 |
| Wells Fargo & Co | 1.07M | 0.16% | +1.43% | Jun 2026 |
Grifols SA ADR company profile
- Company name
- Grifols SA ADR
- Ticker
- GRFS.US
- Exchange
- USA Stocks
- Listed since
- May 17, 2006
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 25,000
- Fiscal year end
- December
- Address
- Parque Empresarial Can Sant Joan, Barcelona, Spain, 08174
- Phone
- 34 935 71 22 00
- Website
- grifols.com
About Grifols SA ADR
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Grifols SA ADR management
10- Mr. Jose Ignacio Abia BuenacheCEO & Director · born 1968
- Mr. Rahul SrinivasanChief Financial Officer · born 1977
- Mr. Lluis Pons GomezSenior Vice President of Strategy & COO Office · born 1984
- Daniel SegarraHead of Investor Relations & Sustainability and Vice President
- Mr. David Ian BellChief Corporate Affairs & Legal Officer · born 1954
- Mr. Enrique de la TorreChief Compliance Officer · born 1973
- Ms. Montse RibasChief Communications and Reputation Officer · born 1969
- Mr. Camille AlpiChief Human Resources & Talent Officer · born 1981
- Mr. Vicente Blanquer TorreChief Quality Officer · born 1961
- Mr. Ignacio Ramal SubiraChief Internal Audit & Enterprise Risk Manager · born 1968